 | Up a level |
Tarantino, I; Warschkow, R; Worni, M; Merati-Kashani, K; Köberle, D; Schmied, B M; Müller, S A; Steffen, T; Cerny, T; Güller, U (2012). Elevated preoperative CEA is associated with worse survival in stage I-III rectal cancer patients. British journal of cancer, 107(2), pp. 266-74. Basingstoke: Nature Publishing Group 10.1038/bjc.2012.267
Laurencet, F; Ballabeni, P; Rufener, B; Hess, U; Cerny, T; Fey, M; Luthi, JM; Plancherel, C; Zulian, GB; Swiss, Group for Clinical Research (SAKK) (2007). The multicenter trial SAKK 37/95 of cladribine, cyclophosphamide and prednisone in the treatment of chronic lymphocytic leukemias and low-grade non-Hodgkin's lymphomas. Acta haematologica, 117(1), pp. 40-7. Basel: Karger 10.1159/000096787
von Rohr, L; Klaeser, B; Joerger, M; Kluckert, T; Cerny, T; Gillessen, S (2007). Increased pulmonary FDG uptake in bleomycin-associated pneumonitis. Onkologie, 30(6), pp. 320-3. Basel: Karger 10.1159/000101517
Heusser, P; Wolf, U; Bertschy, M; Burkhard, R; Ziegler, R; Helwig, S; Cerny, T (2007). Long term sustainability of quality of life in patients with advanced cancer. An explorative study for 12 months after palliative treatment in an anthroposophic hospital. Supportive care in cancer, 15(6), pp. 683-684. Berlin: Springer
Leyvraz, S; Herrmann, R; Guillou, L; Honegger, HP; Christinat, A; Fey, MF; Sessa, C; Wernli, M; Cerny, T; Dietrich, D; Pestalozzi, B; Swiss, Group for Clinical Cancer Research (SAKK) (2006). Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies. British journal of cancer, 95(10), pp. 1342-7. Basingstoke: Nature Publishing Group 10.1038/sj.bjc.6603420
Leyvraz, S; Zweifel, M; Jundt, G; Lissoni, A; Cerny, T; Sessa, C; Fey, M; Dietrich, D; Honegger, HP; Swiss, Group for Clinical Cancer Research (2006). Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas. Annals of oncology, 17(4), pp. 646-51. Oxford: Oxford University Press 10.1093/annonc/mdl020
Betticher, DC; Hsu Schmitz, SF; Tötsch, M; Hansen, E; Joss, C; von Briel, C; Schmid, RA; Pless, M; Habicht, J; Roth, AD; Spiliopoulos, A; Stahel, R; Weder, W; Stupp, R; Egli, F; Furrer, M; Honegger, H; Wernli, M; Cerny, T; Ris, HB; ... (2006). Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. British journal of cancer, 94(8), pp. 1099-106. Basingstoke: Nature Publishing Group 10.1038/sj.bjc.6603075
Pfister, M; Gottstein, Bruno; Kretschmer, Robert; Cerny, T; Cerny, A (2001). Elevated carbohydrate antigen 19-9 (CA 19-9) in patients with Echinococcus infection. Clinical chemistry and laboratory medicine, 39(6), pp. 527-530. Walter de Gruyter 10.1515/CCLM.2001.088
